Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.
(@hongw0)

Goal 2: Reduce Human Disease

International collaboration for genetic and metabolic research on specific human population

During recent years, clinical research including well-organized randomized clinical trials in developed countries generated large database and human biological sample banks. These are valuable resources for human disease research. Mechanisms to encourage and facilitate international collaboration for genetic and metabolic research using database and human biological samples from specific human disease population of international ...more »

Voting

4 net votes
4 up votes
0 down votes
Active
(@golan0)

Goal 2: Reduce Human Disease

Reducing Disparities

Given the dearth of information on cardiovascular, lung, and hematologic outcomes in minorities, NHLBI should develop strategic aims that promote evaluation of these outcomes and potential interactions with kidney disease that disproportionately affect minorities.

Voting

0 net votes
1 up votes
1 down votes
Active
(@anna.adachimejia)

Goal 2: Reduce Human Disease

Design interventions to improve sleep hygiene

Inadequate sleep is associated with risk of obesity. Electronic media devices interfere with our ability to sleep well - they delay sleep, interrupt sleep, and affect sleep quality. However these devices are addictive and ubiquitous. Can we develop interventions to help people obtain adequate sleep?

Voting

2 net votes
2 up votes
0 down votes
Active
(@hloree)

Goal 2: Reduce Human Disease

Devices to Enhance AVF Eligibility and Maturation

There are about 400,000 patients with end-stage renal disease in the U.S. who depend on hemodialysis (HD) for their survival. Creating effective and reliable vascular access sites that can connect patients to HD machines remains a major unmet clinical need. HD patients who use an arteriovenous fistula (AVF) for vascular access live longer, healthier lives and cost less to care for. However, only about 55% of HD patients ...more »

Voting

-13 net votes
2 up votes
15 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Embrace and fund RCTs that enroll heterogeneous samples of patients

Critical care medicine comprises a diffuse array of diseases, syndromes, illnesses and symptoms arising from those sources requiring advanced care by highly trained teams of interdisciplinary professionals. Research is sorely needed on generating evidence that is broadly applicable to a heterogeneous group of patients. This is a major challenge for researchers who enroll critically ill patients into their clinical trials. ...more »

Voting

1 net vote
1 up votes
0 down votes
Active
(@cjoseph)

Goal 2: Reduce Human Disease

Consequences of ABO or Rh Type Specific versus Non-Type Specific Platelet Transfusions

What are the consequences, clinically and immunologically, of ABO or Rh type specific vs. non-type specific platelet transfusions? There is widely varying practice as to ABO and Rh matching of platelets for transfusion. Most studies demonstrate that use of ABO unmatched (non-identical) platelets are associated with increased 1) platelet refractoriness (small randomized trials), 2) red cell transfusion needs and hemolysis, ...more »

Voting

-4 net votes
25 up votes
29 down votes
Active
(@ctong0)

Goal 2: Reduce Human Disease

Heart Failure with Preserved Ejection Fraction Needs better understanding

Effective treatment for Heart Failure with Preserved Ejection Fraction (HFpEF) currently does not exist. Lack of understanding of underlying mechanism(s) probably contributed to this lack of treatment. The well studied neural-hormonal blockade will not work for HFpEF because down stream kinase targets of adrenergic stimulation enhances myocardial relaxation. Consequently, sustain research outside current main stream thinking ...more »

Voting

2 net votes
13 up votes
11 down votes
Active
(@nhlbiforumadministrator1)

Goal 2: Reduce Human Disease

Severe obesity prevention in pediatric and community settings

What novel lifestyle and behavioral modification therapies are needed to prevent or treat youth with severe obesity (>99th percentile for BMI) versus those who are overweight?

 

Can we harness ongoing registries such as POWER (Pediatric Obesity Weight Evaluation Registry) in pediatric primary care (PC) settings to implement novel trials that would link PC and community settings to prevent severe obesity in youth?

Voting

46 net votes
87 up votes
41 down votes
Active